Emcure Pharmaceuticals Ltd - 544210 - Press Release Titled 'Emcure Pharmaceuticals Strengthens Its Commitment To Energy Conservation, Signs PPA With Sunsure Energy For Solar Power'
Please see enclosed herewith a Press Release tilted "Emcure Pharmaceuticals strengthens its commitment to energy conservation, signs PPA with Sunsure Energy for solar power" issued today. Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Acquisition
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we would like to inform that Emcure Pharmaceuticals Limited ("Emcure"), together with its subsidiary, Gennova Biopharmaceuticals Limited ("Gennova"), has entered into a Share Subscription and Shareholders'' Agreement dated July 25, 2024. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the Listing Regulations are being provided. Emcure Pharmaceuticals Ltd - 544210 - Disclosure Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
The details of Key Managerial Personnel severally authorized pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the purpose of determining the materiality of an event or information and for the purpose of making disclosure to Stock Exchange(s). Emcure Pharmaceuticals Ltd - 544210 - Closure of Trading Window
This is to inform that pursuant to the Code of Conduct for regulating, monitoring and reporting of insider trading in the securities of the Company, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading window for trading/ dealing in securities of the Company by the Designated Persons of the Company and their immediate relatives will be closed with effect from Wednesday, July 10, 2024 and shall remain closed upto 48 hours after the declaration of the Financial Results of the Company for the quarter ended June 30, 2024. The date of the Board Meeting for approval of the financial results of the Company for the quarter ended June 30, 2024 shall be intimated in due course. You are requested to take the above information on your records. Emcure Pharma listing: Stock makes solid debut on NSE, BSE with 31% premium
Emcure Pharmaceuticals listing: Stock made a strong market debut as they got listed at Rs 1,325, a 31 per cent premium over the issue price of Rs 1,008 on the NSE and BSE today Emcure Pharmaceuticals Ltd - 544210 - Listing of Equity Shares of Emcure Pharmaceuticals Ltd
Trading Members of the Exchange are hereby informed that effective from July 10, 2024, the equity shares of Emcure Pharmaceuticals Ltd (Scrip Code: 544210) are listed and admitted to dealings on the Exchange in the list of ''B'' Group Securities. For further details please refer to the notice no. 20240709- dated July 09, 2024. Emcure Pharma IPO subscription status: Issue subscribed 75% so far on Day 1
Emcure Pharma IPO subscription status Day 1: Till 2:00 PM, Emcure Pharma IPO was subscribed 75 per cent, led by employees and non-institutional investors